Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine

被引:48
作者
Bartosik-Psujek, H [1 ]
Belniak, E [1 ]
Mitosek-Szewczyk, K [1 ]
Dobosz, B [1 ]
Stelmasiak, Z [1 ]
机构
[1] Med Univ, Dept Neurol, PL-20090 Lublin, Poland
来源
ACTA NEUROLOGICA SCANDINAVICA | 2004年 / 109卷 / 06期
关键词
multiple sclerosis; interleukin-8; RANTES; cladribine; multiple sclerosis therapy;
D O I
10.1111/j.1600-0404.2004.00259.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective - Chemokines are involved in the pathogenesis of multiple sclerosis. The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines - interleukin-8 (IL-8) and RANTES (regulated on activation, normal T cell expressed and secreted). Materials and methods - Twenty-five patients with relapsing-remitting multiple sclerosis were treated with 2-chlorodeoxyadenosine (Cladribine), administered subcutaneously in 6 cycles repeated every 5 weeks. IL-8 and RANTES levels were measured by the enzyme-linked immunoassay (ELISA) method in serum and cerebrospinal fluid (CSF) before and after treatment. Results - After Cladribine treatment the levels of IL-8 decreased significantly in CSF only, whereas the RANTES levels decreased significantly both in CSF and serum. Conclusion - Our results suggest that Cladribine therapy might modify the circulating level of RANTES.
引用
收藏
页码:390 / 392
页数:3
相关论文
共 9 条
  • [1] Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s
    Bonecchi, R
    Bianchi, G
    Bordignon, PP
    D'Ambrosio, D
    Lang, R
    Borsatti, A
    Sozzani, S
    Allavena, P
    Gray, PA
    Mantovani, A
    Sinigaglia, F
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) : 129 - 134
  • [2] The clinical pharmacokinetics of cladribine
    Liliemark, J
    [J]. CLINICAL PHARMACOKINETICS, 1997, 32 (02) : 120 - 131
  • [3] Chemokines - Chemotactic cytokines that mediate inflammation
    Luster, AD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (07) : 436 - 445
  • [4] Expression of chemokine receptors in the different clinical forms of multiple sclerosis
    Martínez-Cáceres, EM
    Espejo, C
    Brieva, L
    Pericot, I
    Tintoré, M
    Sáez-Torres, I
    Montalban, X
    [J]. MULTIPLE SCLEROSIS, 2002, 8 (05): : 390 - 395
  • [5] Michalowska-Wender G, 1999, Neurol Neurochir Pol, V33, P749
  • [6] Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis
    Rudick, RA
    Cookfair, DL
    Simonian, NA
    Ransohoff, RM
    Richert, JR
    Jacobs, LD
    Herndon, RM
    Salazar, AM
    Fischer, JS
    Granger, CV
    Goodkin, DE
    Simon, JH
    Bartoszak, DM
    Bourdette, DN
    Braiman, J
    Brownscheidle, CM
    Coats, ME
    Cohan, SL
    Dougherty, DS
    Kinkel, RP
    Mass, MK
    Munchsauer, FE
    O'Reilly, K
    Priore, RL
    Pullicino, PM
    Scherokman, BJ
    Wende, K
    Weinstock-Guttman, B
    Whitham, RH
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1999, 93 (1-2) : 8 - 14
  • [7] Differential release of β-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis
    Sindern, E
    Niederkinkhaus, Y
    Henschel, M
    Ossege, LM
    Patzold, T
    Malin, JP
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2001, 104 (02): : 88 - 91
  • [8] Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients
    Sorensen, TL
    Tani, M
    Jensen, J
    Pierce, V
    Lucchinetti, C
    Folcik, VA
    Qin, SX
    Rottman, J
    Sellebjerg, F
    Strieter, RM
    Frederiksen, JL
    Ransohoff, RM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06) : 807 - 815
  • [9] Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis
    Zhang, GX
    Baker, CM
    Kolson, DL
    Rostami, AM
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2000, 6 (01) : 3 - 13